Revenue Breakdown
Composition ()
No data
Revenue Streams
Biogen Inc (BIIB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Spinal Muscular Atrophy-SPINRAZA, accounting for 18.1% of total sales, equivalent to $449.00M. Other significant revenue streams include MS product revenues-TYSABRI and MS product revenues-Fumarate. Understanding this composition is critical for investors evaluating how BIIB navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Biogen Inc maintains a gross margin of 67.81%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.55%, while the net margin is 12.89%. These profitability ratios, combined with a Return on Equity (ROE) of 7.70%, provide a clear picture of how effectively BIIB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BIIB competes directly with industry leaders such as RPRX and INSM. With a market capitalization of $28.56B, it holds a significant position in the sector. When comparing efficiency, BIIB's gross margin of 67.81% stands against RPRX's 100.00% and INSM's 83.82%. Such benchmarking helps identify whether Biogen Inc is trading at a premium or discount relative to its financial performance.
